FDA Approved Products
4,491 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
ACHROMYCIN
hydrocortisone; tetracycline hydrochloride
LOE Approaching
Pfizer
OPHTHALMIC · OINTMENT
1980
NDA30/100
ACHROMYCIN
tetracycline hydrochloride
LOE Approaching
Bausch + Lomb
OPHTHALMIC · SUSPENSION/DROPS
skin infection in minor cutsscrapes+1
1955
NDA30/100
ACHROMYCIN
procaine hydrochloride; tetracycline hydrochloride
LOE Approaching
Pfizer
INJECTION · INJECTABLE
1954
NDA30/100
ACHROMYCIN
tetracycline hydrochloride
LOE Approaching
Bausch + Lomb
OPHTHALMIC · OINTMENT
skin infection in minor cutsscrapes+1
1957
NDA30/100
ACHROMYCIN
tetracycline hydrochloride
LOE Approaching
Pfizer
INJECTION · INJECTABLE
skin infection in minor cutsscrapes+1
1953
NDA30/100
ACHROMYCIN V
tetracycline hydrochloride
LOE Approaching
ORAL · CAPSULE
the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenesStreptococcus pneumoniae+1
1957
NDA30/100
ACHROMYCIN V
tetracycline hydrochloride
LOE Approaching
Pfizer
ORAL · SUSPENSION
skin infection in minor cutsscrapes+1
1955
NDA30/100
ACIPHEX
rabeprazole sodium
LOE Approaching
Viatris (2)
ORAL · TABLET, DELAYED RELEASE
daytimenighttime heartburn+4
1999
NDA30/100
ACIPHEX
rabeprazole sodium
LOE Approaching
Eisai
Oral · Tablet, Delayed Release
daytimenighttime heartburn+4
2002
NDA30/100
ACLOVATE
alclometasone dipropionate
LOE Approaching
Sandoz
TOPICAL · CREAM
1982
NDA30/100
ACLOVATE
alclometasone dipropionate
LOE Approaching
Sandoz
TOPICAL · OINTMENT
1982
NDA30/100
ACTH
corticotropin
LOE Approaching
Pfizer
INJECTION · INJECTABLE
invasive disease caused by Haemophilus influenzae type b
1952
NDA30/100
ACTHAR
corticotropin
LOE Approaching
Sanofi
INJECTION · INJECTABLE
exacerbations of multiple sclerosis in adultsacute exacerbations of multiple sclerosis in adults+2
1950
NDA30/100
ACTIGALL
ursodiol
LOE Approaching
Teva
ORAL · CAPSULE
gallstone formation in obese patients experiencing rapid weight loss
1987
NDA30/100
ACTINEX
masoprocol
LOE Approaching
TOPICAL · CREAM
1992
NDA30/100
ACTIQ
fentanyl citrate
LOE Approaching
Teva
TRANSMUCOSAL · TROCHE/LOZENGE
breakthrough pain in cancer patients 16 years of ageolder+1
1998
NDA30/100
ACTISITE
tetracycline hydrochloride
LOE Approaching
PERIODONTAL · FIBER, EXTENDED RELEASE
skin infection in minor cutsscrapes+1
1994
NDA30/100
ACTIVELLA
estradiol; norethindrone acetate
LOE Approaching
Novo Nordisk
ORAL · TABLET
a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Treatment of Moderate to Severe Symptoms of VulvarVaginal Atrophy due to Menopause Limitations of Use :+3
2000
NDA30/100
ACTIVELLA
estradiol/norethindrone acetate
LOE Approaching
ORAL · TABLET
a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Prevention of Postmenopausal Osteoporosis Lopreeza 1 mg/0a woman with a uterus for: Treatment of Moderate to Severe Symptoms of Vulvar+2
1998
NDA30/100
ACTIVELLA
estradiol; norethindrone acetate
LOE Approaching
Novo Nordisk
ORAL · TABLET
a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Treatment of Moderate to Severe Symptoms of VulvarVaginal Atrophy due to Menopause Limitations of Use :+3
2006
NDA30/100
ACTONEL
risedronate sodium
LOE Approaching
ORAL · TABLET
Paget's disease of bone in menwomen+1
1998
NDA30/100
ACTONEL WITH CALCIUM (COPACKAGED)
calcium carbonate; risedronate sodium
LOE Approaching
AbbVie
ORAL · TABLET
2005
NDA30/100
ACTOS
pioglitazone
LOE Approaching
Takeda
ORAL · TABLET
type 2 diabetes mellitus in multiple clinical settingstype 2 diabetes mellitus+3
1999
NDA30/100
ACTRON
ketoprofen
LOE Approaching
Bayer
ORAL · TABLET
the signssymptoms of rheumatoid arthritis+4
1995
SMNDA30/100